Treatment Options

For most subtypes of peripheral T-cell lymphoma (PTCL), the initial treatment is typically a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), or other multidrug regimens. Because most patients with PTCL will relapse, some physicians recommend high- dose chemotherapy followed by an autologous stem cell transplant (a type of stem cell transplant in which the patient receives his or her own stem cells, collected several weeks before the transplant).

For CD30-expressing PTCLs, brentuximab vedotin (Adcetris) is now approved for use in combination with cyclophosphamide, doxorubicin, and prednisone as initial treatment. In very specific cases, radiation therapy is given after chemotherapy as a part of first-line treatment. Because many patients with PTCL will relapse, some physicians recommend high-dose chemotherapy followed by an autologous SCT for certain patients

Many new drugs are being studied in clinical trials for the treatment of PTCL, including:

• Azacitidine (CC-486)
• Bendamustine (Treanda)
• Bortezomib (Velcade)
• Cemiplimab (Libtayo)
• Devimistat (CPI 613)
• Durvalumab (Imfinzi)
• Duvelisib (Copiktra)
• GDP (gemcitabine, dexamethasone, and cisplatin)
• Lacutamab (IPH4102)
• Lenalidomide (Revlimid)
• MEDI-570
• Nivolumab (Opdivo)
• Pembrolizumab (Keytruda)
• Ruxolitinib (Jakafi)
• Valemetostat (DS-3201b)
• Venetoclax (Venclexta)

Learn More

To learn more about PTCL, download the Peripheral T-Cell Lymphoma Fact Sheet. Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Helpline at (800) 500-9976 or helpline@lymphoma.org.